喜訊! 九價HPV疫苗在我國獲批上市!

Residents of the Chinese mainland now have access to a nine-way HPV vaccine -- which works against up to nine types of the human papillomavirus -- after the medication was given the nod by China's top drug administration.

我國最高藥品管理部門日前批准了九價人乳頭狀瘤病毒疫苗（即HPV疫苗）上市，這意味着大陸居民將可接種這種能對抗9種類型的HPV病毒的疫苗。

It is the third HPV vaccine approved for the mainland market since the middle of last year.

這是自去年年中以來大陸市場批准上市的第三款HPV疫苗。

Such vaccines have proved effective against cervical cancer, the second most common cancer among Chinese women aged 15 to 44 after breast cancer.

該種疫苗可有效預防宮頸癌，宮頸癌是我國15至44歲女性中的第二大高發癌症，僅次於乳腺癌。

Experts say China has around 130,000 new cases of cervical cancer each year, accounting for more than 28 percent of the world total.

專家們表示，中國每年有大約13萬例宮頸癌新發病例，佔世界總數的28%以上。

Before the availability of vaccines on the mainland, people had to travel to other countries or to Hong Kong to get the vaccine, which is injected in three separate doses over a span of six months.

在中國大陸批准該疫苗之前，人們必須到香港或其他國家去接種，具體接種需要在6個月內完成3次注射。

Australia -- the first country to offer free HPV vaccinations for 12-and 13-year-old girls, and catch-up programs for girls and women under 26 -- has seen a sharp decline in HPV infections since the introduction of a national school-based vaccination program in 2007.

澳大利亞是第一個爲12-13歲女孩提供免費HPV疫苗、爲26歲以下女性提供免費追趕計劃的國家。自2007年推出一項國家性的基於學校的疫苗接種計劃以來，該國的HPV感染人數急劇下降。

Within a decade, the proportion of 18-to 24-year-old women with HPV in the country has fallen from 22.7 percent to 1.5 percent.

在過去十年間，澳大利亞18至24歲年輕女性感染HPV的比例已經從原先的22.7%下降到了1.5%。